Xpovio® (selinexor) – Expanded indication
On December 18, 2020 - Karyopharm Therapeutics announced the FDA approval of Xpovio (selinexor), in combination with bortezomib (eg, Velcade®) and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Top